* Gritstone bio Inc GRTS.OQ GRTS.O is expected to show a
fall
in quarterly revenue when it reports results on May 9 for the
period ending March 31 2024
* The Emeryville California-based company is expected to
report a
54.8% decrease in revenue to $1.104 million from $2.44 million a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Gritstone bio Inc is for
a
loss of 32 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 4.4%
in the last three months.
* Wall Street's median 12-month price target for Gritstone
bio Inc
is $4.00, above its last closing price of $1.01.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.31 -0.33 -0.26 Beat 20.7
Sep. 30 2023 -0.31 -0.33 -0.33 Met 0.9
Jun. 30 2023 -0.33 -0.35 -0.31 Beat 10.5
Mar. 31 2023 -0.33 -0.33 -0.30 Beat 10.3
Dec. -0.31 -0.34 -0.30 Beat 12.8
31 2022
Jan. 1 0001 -0.37 -0.40 -0.35 Beat 12.1
Jun. 30 2022 -0.39 -0.40 -0.34 Beat 14.1
Mar. 31 2022 -0.35 -0.37 -0.34 Beat 7.5
This summary was machine generated May 8 at 02:03 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)